Overview

High Potency Statins and the Risk of Diabetes

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Statins are a class of cholesterol lowering medications that are prescribed for the prevention and treatment of cardiovascular disease. The purpose of this study is to determine if there is an increased risk of new diabetes when exposed to high potency statins, compared to low potency statins, among patients who had a recent cardiovascular event or procedure. The investigators will carry out separate population based cohort studies using administrative health care databases in eight jurisdictions in Canada, the US, and the UK. The cohort will be defined by the initiation of a statin, with follow-up until a diagnosis of incident diabetes or a prescription for insulin or an oral antidiabetic medication. The results from the separate sites will be combined in a meta-analysis to provide an overall assessment of the risk of new onset diabetes in subjects starting a statin.
Details
Lead Sponsor:
Canadian Network for Observational Drug Effect Studies, CNODES
Collaborators:
Canadian Institutes of Health Research (CIHR)
Drug Safety and Effectiveness Network, Canada
Treatments:
Atorvastatin
Atorvastatin Calcium
Dihydromevinolin
Fluvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
L 647318
Lovastatin
Pravastatin
Rosuvastatin Calcium
Simvastatin